Peer-influenced content. Sources you trust. No registration required. This is HCN.

OBR OncologyAlpine Stops Enrollment in Cancer Drug Study After Second Patient Death This Year

According to reports, the second patient who passed away during the Phase 1 test of the cancer drug davoceticept by Alpine Immune Sciences experienced the same cardiovascular issue as the first patient.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form